Skip to search formSkip to main contentSkip to account menu

JNJ-42756493

Known as: pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 
An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, JNJ… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and… 
Review
2019
Review
2019
Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases expressed on the cell membrane that play… 
Highly Cited
2018
Highly Cited
2018
4503Background: ERDA is an FGFR inhibitor with activity in pts with mUC and FGFRalt. FGFRalt occur in 10-20% of mUC and are… 
Highly Cited
2017
Highly Cited
2017
Fibroblast growth factor (FGF) signaling plays critical roles in key biological processes ranging from embryogenesis to wound… 
Review
2016
Review
2016
  • M. Katoh
  • International journal of molecular medicine
  • 2016
  • Corpus ID: 18926318
Fibroblast growth factor (FGF)2, FGF4, FGF7 and FGF20 are representative paracrine FGFs binding to heparan-sulfate proteoglycan… 
Highly Cited
2015
Highly Cited
2015
PURPOSE JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. This first… 
Highly Cited
2015
Highly Cited
2015
Purpose: Oncogenic fusions consisting of fibroblast growth factor receptor (FGFR) and TACC are present in a subgroup of… 
Review
2015
Review
2015
Fibroblast growth factor receptor (FGFR) signaling is involved in multiple biological processes, including cell proliferation… 
2014
2014
2501 Background: JNJ-42756493 is an orally bioavailable FGFR 1, 2, 3 and 4 inhibitor with nanomolar antitumor activity in cell…